Figure 7.

Acute changes in GFR slopes with three distinct classes of drugs with unique mechanisms that slow kidney disease progression associated diabetes. A: Estimated mean changes (SE) in GFR (mL/min/1.73 m²) from baseline through follow-up in three drug interventions (127). B: Rate of eGFR decline between finerenone and placebo. Despite equivalent GFR at baseline, the finerenone group shows stabilization of slowed GFR declines (96) and higher GFR declines at 4 months, which are associated with better long-term outcomes. C: Initial decline in GFR decline in the empagliflozin group compared with placebo at month 4 (128). The slopes eventually cross over at week 76, and analyses of the slopes in the long-term phase shows higher GFR decline in the placebo group than the empagliflozin group, P < 0.05. EMPA-REG Outcome, BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; LS, least squares.